標(biāo)題: Titlebook: Data Monitoring in Clinical Trials; A Case Studies Appro David L. DeMets,Curt D. Furberg,Lawrence M. Friedm Book 2006 Springer-Verlag New Y [打印本頁] 作者: hexagon 時間: 2025-3-21 18:25
書目名稱Data Monitoring in Clinical Trials影響因子(影響力)
書目名稱Data Monitoring in Clinical Trials影響因子(影響力)學(xué)科排名
書目名稱Data Monitoring in Clinical Trials網(wǎng)絡(luò)公開度
書目名稱Data Monitoring in Clinical Trials網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Data Monitoring in Clinical Trials被引頻次
書目名稱Data Monitoring in Clinical Trials被引頻次學(xué)科排名
書目名稱Data Monitoring in Clinical Trials年度引用
書目名稱Data Monitoring in Clinical Trials年度引用學(xué)科排名
書目名稱Data Monitoring in Clinical Trials讀者反饋
書目名稱Data Monitoring in Clinical Trials讀者反饋學(xué)科排名
作者: Urologist 時間: 2025-3-21 21:58
Data and Safety Monitoring in the Beta-Blocker Heart Attack Trial: Early Experience in Formal Monitoarction. The primary outcome was total mortality. The trial ended nine months ahead of schedule because of clear benefit from propranolol. The independent monitoring committee considered several newly developed statistical approaches in recommending early stopping, as well as other factors, includin作者: 作繭自縛 時間: 2025-3-22 01:52 作者: 頭盔 時間: 2025-3-22 07:57
Early Termination of the Stroke Prevention in Atrial Fibrillation I Trial: Protecting Participant Innts with nonvalvular atrial fibrillation. Participants were categorized as either warfarin-eligible or warfarin-ineligible based on contraindications to or refusal of anticoagulation, and interim efficacy monitoring examined treatment effects separately by warfarin eligibility. The planned primary a作者: 消滅 時間: 2025-3-22 10:38 作者: 的事物 時間: 2025-3-22 15:59
Data Monitoring in the AIDS Clinical Trials Group Study #981: Conflicting Interim Results200 mg daily) with clotrimazole lozenges (10mg, five times daily) for prevention of invasive fungal infections in patients with advanced HIV disease. At the fourth DSMB review of the study in November 1992, the patients on fluconazole had a significantly lower risk of invasive, serious and superfici作者: 的事物 時間: 2025-3-22 20:40
Challenges in Monitoring the Breast Cancer Prevention Trialcal Breast and Bowel Project (NSABP), a National Cancer Institute (NCI)-funded cancer cooperative group. The primary hypothesis tested was whether tamoxifen, a drug that is beneficial for treatment of breast cancer, was effective in preventing the occurrence of cancer in women at increased risk. The作者: 空氣傳播 時間: 2025-3-22 21:32 作者: Mortar 時間: 2025-3-23 03:50
Stopping the Randomized Aldactone Evaluation Study Early for Efficacy of daily spironolactone to standard therapy would reduce the risk of all-cause mortality in patients with severe heart failure as a result of systolic left ventricular dysfunction. The Data Safety Monitoring Board (DSMB) for RALES reviewed data on safety and efficacy throughout the trial using pre-作者: Demonstrate 時間: 2025-3-23 06:34
Data Monitoring in the Heart Outcomes Prevention Evaluation and the Clopidogrel in Unstable Angina tin the data, but also to avoid the loss of important treatment information concerning secondary outcomes, key subgroups, and patient safety data. For the Heart Outcomes Prevention Evaluation (HOPE) and Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) trials, their Data and 作者: 脾氣暴躁的人 時間: 2025-3-23 13:08 作者: hermetic 時間: 2025-3-23 13:58
Breaking New Ground: Data Monitoring in the Coronary Drug Projectmplex process. It may involve, among other things, the need to (1) determine whether the observed treatment differences are likely to represent real effects and are not due to chance; (2) weigh the importance of different response variables, some possibly trending in favor of the treatment and some 作者: creatine-kinase 時間: 2025-3-23 22:01
The Data Monitoring Experience in the Cardiac Arrhythmia Suppression Trial: The Need to Be Prepared s with a recent myocardial infarction would reduce the incidence of sudden death and total mortality, using three drugs known to suppress cardiac arrhythmias. Patients were randomized to receive either active drug or a matching placebo. The trial was terminated after only 15% of the planned-for even作者: 松果 時間: 2025-3-23 23:50 作者: 窩轉(zhuǎn)脊椎動物 時間: 2025-3-24 03:08 作者: largesse 時間: 2025-3-24 06:38
Richard Lai,Ajin Jirachiefpattanaetic retinopathy. Benefit was detected early, but there where concerns about the possibility of late adverse effects. Calculations using projected blindness and death rates reassured the data monitoring committee that even large late adverse affects would not offset the early benefit already observed.作者: Tracheotomy 時間: 2025-3-24 13:05
https://doi.org/10.1007/0-387-30107-0Division; Host; LDA; Statistica; complexity; design; eXist; evaluation; form; monitor; monitoring; object; repor作者: 飛鏢 時間: 2025-3-24 18:50 作者: 同義聯(lián)想法 時間: 2025-3-24 19:46 作者: GUILE 時間: 2025-3-24 23:27
http://image.papertrans.cn/d/image/262983.jpg作者: Intersect 時間: 2025-3-25 05:57 作者: Harass 時間: 2025-3-25 09:06
Richard Lai,Ajin Jirachiefpattanaarction. The primary outcome was total mortality. The trial ended nine months ahead of schedule because of clear benefit from propranolol. The independent monitoring committee considered several newly developed statistical approaches in recommending early stopping, as well as other factors, includin作者: 陳腐的人 時間: 2025-3-25 12:18 作者: caldron 時間: 2025-3-25 16:25 作者: Flustered 時間: 2025-3-25 23:57 作者: 小丑 時間: 2025-3-26 00:20
https://doi.org/10.1007/978-3-030-50405-2200 mg daily) with clotrimazole lozenges (10mg, five times daily) for prevention of invasive fungal infections in patients with advanced HIV disease. At the fourth DSMB review of the study in November 1992, the patients on fluconazole had a significantly lower risk of invasive, serious and superfici作者: MOAT 時間: 2025-3-26 07:45 作者: 大廳 時間: 2025-3-26 11:25
Communication Rights and Social Justice91 patients with New York Heart Class II–IV heart failure and LVEF ≤0.40. The two primary objectives were to determine the effect of metoprolol CR/XL on all-cause mortality and on the combined endpoint of all-cause mortality or all-cause hospitalizations (time to first event). There was a two-week p作者: faddish 時間: 2025-3-26 12:51
Media Justice and Communication Rights of daily spironolactone to standard therapy would reduce the risk of all-cause mortality in patients with severe heart failure as a result of systolic left ventricular dysfunction. The Data Safety Monitoring Board (DSMB) for RALES reviewed data on safety and efficacy throughout the trial using pre-作者: 鼓掌 時間: 2025-3-26 18:20
The Essentials of Nursing Management Seriesin the data, but also to avoid the loss of important treatment information concerning secondary outcomes, key subgroups, and patient safety data. For the Heart Outcomes Prevention Evaluation (HOPE) and Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) trials, their Data and 作者: 啤酒 時間: 2025-3-27 00:57
The Essentials of Nursing Management Seriesomparing candesartan with placebo in patients with chronic heart failure (CHF) who (1) were intolerant to angiotensin converting enzyme (ACE)-inhibitor and had left ventricular ejection fraction (LVEF) ≤ 40%, (2)) were on ACE-inhibitor and had LVEF ≤ 40% or (3)) had LVEF > 40%. CHARM provides an int作者: 陪審團(tuán)每個人 時間: 2025-3-27 04:04
The Essentials of Nursing Management Seriesmplex process. It may involve, among other things, the need to (1) determine whether the observed treatment differences are likely to represent real effects and are not due to chance; (2) weigh the importance of different response variables, some possibly trending in favor of the treatment and some 作者: 彈藥 時間: 2025-3-27 08:06
The Patient-Surgeon Relationships with a recent myocardial infarction would reduce the incidence of sudden death and total mortality, using three drugs known to suppress cardiac arrhythmias. Patients were randomized to receive either active drug or a matching placebo. The trial was terminated after only 15% of the planned-for even作者: Institution 時間: 2025-3-27 10:48
Communication with Young Peoplestudies with milrinone, a cyclic AMP-enhancing positive inotropic agent. Earlier studies had shown positive effects of milrinone on cardiac function and exercise performance in patients with chronic heart failure. To determine the effect of milrinone on mortality, patients with severe chronic heart 作者: Basal-Ganglia 時間: 2025-3-27 14:22 作者: 災(zāi)禍 時間: 2025-3-27 21:09 作者: chapel 時間: 2025-3-27 21:58 作者: 貧窮地活 時間: 2025-3-28 02:15
The Patient-Surgeon Relationshipythmias. Patients were randomized to receive either active drug or a matching placebo. The trial was terminated after only 15% of the planned-for events had been observed with an unexpected but dramatic increase in sudden death and total mortality in those patients receiving two of the active therapies. Later, the third drug was also discontinued.作者: 自由職業(yè)者 時間: 2025-3-28 10:04 作者: delegate 時間: 2025-3-28 13:23 作者: 反應(yīng) 時間: 2025-3-28 18:14
Early Termination of the Diabetes Control and Complications Trialy caused these complications. The study was terminated one year ahead of schedule by the monitoring board. This paper describes the medical, ethical, and statistical challenges faced by the study group and the monitoring board.作者: 暫停,間歇 時間: 2025-3-28 21:12
The Essentials of Nursing Management Seriese study not being double-blind) in the medical management of patients or in the diagnosis of events; and (5) evaluate treatment effects in subgroups of the study participants. Experiences from the Coronary Drug Project in making decisions for early termination and for non-termination of treatment groups are described.作者: 眉毛 時間: 2025-3-29 01:40
Communication with Young Peoplenated after 20 months, before its scheduled completion, based on an observed adverse effect of milrinone on survival. This paper describes the experience of the Data Monitoring and Safety Monitoring Board (DSMB) in dealing with an emerging negative trend in survival when there were other known beneficial effects of the drug.作者: Meditate 時間: 2025-3-29 05:26
Breaking New Ground: Data Monitoring in the Coronary Drug Projecte study not being double-blind) in the medical management of patients or in the diagnosis of events; and (5) evaluate treatment effects in subgroups of the study participants. Experiences from the Coronary Drug Project in making decisions for early termination and for non-termination of treatment groups are described.作者: 材料等 時間: 2025-3-29 10:45
Data Monitoring in the Prospective Randomized Milrinone Survival Evaluation: Dealing With an Agonizinated after 20 months, before its scheduled completion, based on an observed adverse effect of milrinone on survival. This paper describes the experience of the Data Monitoring and Safety Monitoring Board (DSMB) in dealing with an emerging negative trend in survival when there were other known beneficial effects of the drug.作者: Acetabulum 時間: 2025-3-29 12:25 作者: uncertain 時間: 2025-3-29 19:21 作者: AMPLE 時間: 2025-3-29 21:06
Protocol Specification and Designy caused these complications. The study was terminated one year ahead of schedule by the monitoring board. This paper describes the medical, ethical, and statistical challenges faced by the study group and the monitoring board.作者: Ingenuity 時間: 2025-3-30 02:59 作者: Fortify 時間: 2025-3-30 04:49
Communication Protocol Performancel event. Several additional factors were involved, including little or no trend in either CVD mortality or stroke, although the numbers of events were too low to distinguish between small benefit, no effect, and small harm. These circumstances suggested clear evidence for aspirin in preventing a fir作者: 消瘦 時間: 2025-3-30 09:45 作者: Dictation 時間: 2025-3-30 16:15
https://doi.org/10.1007/978-3-030-50405-2ducing overall mortality, thus vindicating the recommendations of the DSMB to keep the trial open until the planned follow-up had been completed. This paper is a review of the DSMB process for this study, and how the Board dealt with the challenges of interpretation of apparently contradictory evide作者: phlegm 時間: 2025-3-30 20:32
Claudia Padovani,Andrew Calabrese multiple endpoints of interest, other concerns that were addressed included a reassessment of study sample size and power subsequent to a lengthy suspension of accrual during the trial and handling the occurrence of an unexpected ocular toxicity in association with tamoxifen. Although there were nu作者: 不可磨滅 時間: 2025-3-31 00:22 作者: DAMP 時間: 2025-3-31 02:03
Media Justice and Communication Rightsths in the placebo group and 269 in the spironolactone group for an estimated hazard ratio of 0.78 (p = 0.00018). The board recommended early termination of the trial because the observed Z-value of 3.75 exceeded the pre-specified critical value of 2.79 and the data on mortality showed consistency a作者: compassion 時間: 2025-3-31 05:24
The Essentials of Nursing Management Seriesall-cause mortality in the overall program. The overarching principle of the DSMC was proof beyond a reasonable doubt that would be likely to influence clinical practice..There were significant treatment differences in all-cause mortality at several interim analyses, and the statistical stopping gui作者: PHIL 時間: 2025-3-31 09:58
Introduction to Case Studies Showing Benefit from the Intervention作者: 漫不經(jīng)心 時間: 2025-3-31 15:20
Introduction to Case Studies Showing Harmful Effects of the Intervention作者: Biomarker 時間: 2025-3-31 20:30
Book 2006s presented by many distinguished clinical trial experts, illustrates the complexity of this monitoring process. The editors provide an overview of the process and a summary of a multitude of the lessons learned from the cases presented...This book should be useful to anyone serving on a data and sa作者: Ascendancy 時間: 2025-3-31 21:49
Data Monitoring for the Aspirin Component of the Physicians’ Health Study: Issues in Early Terminatil event. Several additional factors were involved, including little or no trend in either CVD mortality or stroke, although the numbers of events were too low to distinguish between small benefit, no effect, and small harm. These circumstances suggested clear evidence for aspirin in preventing a fir作者: MAIM 時間: 2025-4-1 02:18 作者: 廚師 時間: 2025-4-1 06:38
Data Monitoring in the AIDS Clinical Trials Group Study #981: Conflicting Interim Resultsducing overall mortality, thus vindicating the recommendations of the DSMB to keep the trial open until the planned follow-up had been completed. This paper is a review of the DSMB process for this study, and how the Board dealt with the challenges of interpretation of apparently contradictory evide作者: 含糊 時間: 2025-4-1 13:29
Challenges in Monitoring the Breast Cancer Prevention Trial multiple endpoints of interest, other concerns that were addressed included a reassessment of study sample size and power subsequent to a lengthy suspension of accrual during the trial and handling the occurrence of an unexpected ocular toxicity in association with tamoxifen. Although there were nu作者: Individual 時間: 2025-4-1 16:55
Data Monitoring Experience in the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Farst was to review all reported Serious Adverse Events (SAEs) on a monthly basis and produce a short report to the sponsor aimed for regulatory agencies. This was done because the sponsor had received a waiver for expedited reporting of SAEs from regulatory agencies including the U.S. Food and Drug A
